GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avenir Wellness Solutions Inc (OTCPK:AVRW) » Definitions » Debt-to-EBITDA

Avenir Wellness Solutions (Avenir Wellness Solutions) Debt-to-EBITDA : -0.98 (As of Sep. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Avenir Wellness Solutions Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Avenir Wellness Solutions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $8.50 Mil. Avenir Wellness Solutions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil. Avenir Wellness Solutions's annualized EBITDA for the quarter that ended in Sep. 2023 was $-8.64 Mil. Avenir Wellness Solutions's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.98.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Avenir Wellness Solutions's Debt-to-EBITDA or its related term are showing as below:

AVRW' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.51   Med: -0.6   Max: -0.05
Current: -0.84

During the past 8 years, the highest Debt-to-EBITDA Ratio of Avenir Wellness Solutions was -0.05. The lowest was -2.51. And the median was -0.60.

AVRW's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs AVRW: -0.84

Avenir Wellness Solutions Debt-to-EBITDA Historical Data

The historical data trend for Avenir Wellness Solutions's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avenir Wellness Solutions Debt-to-EBITDA Chart

Avenir Wellness Solutions Annual Data
Trend Mar15 Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial -0.87 -0.05 -0.60 -2.51 -0.61

Avenir Wellness Solutions Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.02 -0.36 -13.53 -2.13 -0.98

Competitive Comparison of Avenir Wellness Solutions's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Avenir Wellness Solutions's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avenir Wellness Solutions's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avenir Wellness Solutions's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Avenir Wellness Solutions's Debt-to-EBITDA falls into.



Avenir Wellness Solutions Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Avenir Wellness Solutions's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.015 + 0.046) / -16.455
=-0.61

Avenir Wellness Solutions's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.504 + 0) / -8.64
=-0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Avenir Wellness Solutions  (OTCPK:AVRW) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Avenir Wellness Solutions Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Avenir Wellness Solutions's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Avenir Wellness Solutions (Avenir Wellness Solutions) Business Description

Traded in Other Exchanges
N/A
Address
5805 Sepulveda Boulevard, Suite 801, Sherman Oaks, CA, USA, 91411
Avenir Wellness Solutions Inc is a broad wellness platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems. The technology, which is based on approximately 15 current patents, offers several immediate- and controlled-release delivery vehicles designed to improve product efficacy, safety, and consumer experience for a wide range of active ingredients. The company sells its product under the brand names Seratopical, Seratopical Revolution, SeraLabs, and Nutri-Strips.
Executives
Robert J Costantino director 5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Joel M Bennett officer: CFO,CAO, Treasurer & Secretary 22619 PACIFIC COAST HIGHWAY, MALIBU CA 90265
Gerald Bagg director C/O CURE PHARMACEUTICAL HOLDING CORP., 5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Nancy Duitch officer: Chief Strat Officer-Wellness 15950 ROYAL OAK RD, ENCINO CA 91436
Robert Steven Davidson director, officer: CEO & Director 5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Jonathan Berlent officer: Chief Business Officer 1620 BEACON PLACE, OXNARD CA 93033
John K Bell director 38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8
Anna Goldin director 1620 BEACON STREET, OXNARD CA 93033
Lauren Chung director 1620 BEACON STREET, OXNARD CA 93033
Michael Redard officer: Chief Financial Officer 1620 BEACON PLACE, OXNARD CA 93033
Joshua Held director 1620 BEACON PLACE, OXNARD CA 93033
Climate Change Investigation, Innovation & Investment Company, Llc 10 percent owner 12 SAN RAFAEL AVE, BELVEDERE CA 94920
Ruben Jr King-shaw director 1620 BEACON PLACE, OXNARD CA 93033
Gene Z Salkind director 5805 SEPULVEDA BLVD., SUITE 801, SHERMAN OAKS CA 91411
Alex Katz officer: CFO 1233 FAIRY HILL ROAD, RYDAL PA 19046

Avenir Wellness Solutions (Avenir Wellness Solutions) Headlines

From GuruFocus

CURE Pharmaceutical Letter to Shareholders

By ACCESSWIRE ACCESSWIRE 12-15-2022

Avenir Wellness Letter to Stockholders

By ACCESSWIRE ACCESSWIRE 04-25-2023